# Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

> **NCT01978236** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Melanoma and Brain Metastases

## Interventions

- **DRUG:** Dabrafenib 150 mg
- **DRUG:** Trametinib 2.0 mg

## Key facts

- **NCT ID:** NCT01978236
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-08
- **Primary completion:** 2017-04-26
- **Final completion:** 2017-04-26
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This study was terminated due to the limited enrollment.
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978236, "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01978236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*